Ozuriftamab vedotin
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575) . Ozuriftamab vedotin has antitumor activities[1].
Product Specifications
CAS Number
[2460400-11-5]
Product Name Alternative
BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC
UNSPSC
12352211
Target
Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ozuriftamab-vedotin.html
Purity
99.65
Smiles
[Ozuriftamabvedotin]
References & Citations
[1]Alan L. Ho, et al. Abstract PO-007: A phase 2 open-label study of conditionally active biologic, ozuriftamab vedotin (BA3021) in PD-1/L1 failure patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res (2023) 29 (18_Supplement) : PO-007.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6297647-01 0.2 mL
FAF2, CT (FAF2, ETEA, KIAA0887, UBXD8, UBXN3B, FAS-associated factor 2, Protein ETEA, UBX domain-containing protein 3B, UBX domain-containing protein 8) (AP)
Ask
View Details